340B Decision Insights 2020
22 January 20
| Jackson Tate and Sam Eaquinto
The 340B program is considered a critical savings opportunity for covered entities and their contracted pharmacies, and over the past couple of years, KLAS has noted an increase in provider organization purchase decisions in the third-party administrator space. Some organizations are putting out RFPs because their current contracts are ending, but many others are seeking out solutions to fill the functionality and service gaps of their current 340B vendor. Newer market entrants, such as PSG and RxStrategies, represent additional options to consider alongside the already-established market players. While organizations continue to look for new technology and functionality in potential vendor partners, factors like service, support, and relationships have proven to be key to long-term customer success.